In Japan, a clinic cannot simply start offering stem cell or other cell-based treatments. Since November 2014, the Act on the Safety of Regenerative Medicine has required every hospital or clinic to write a provision plan for each treatment, have it reviewed by a government-certified committee, and file it with the Ministry of Health, Labour and Welfare (MHLW) before the first patient is treated. How strict that process is depends on which of three risk classes the treatment falls into.

This guide explains the classes, the committees, the filing routes, what clinics must keep reporting afterward, and what happens when they skip the process.

What the Act is and why it exists

The law is the Act on the Safety of Regenerative Medicine (再生医療等の安全性の確保等に関する法律, Act No. 85 of 2013), sometimes translated as the Act on Securing the Safety of Regenerative Medicine. MHLW states that it took effect in November 2014, together with amendments to Japan's main pharmaceuticals and medical devices law.

Article 1 sets out its purpose: to establish the measures that anyone providing regenerative medicine must take to secure safety and respect bioethics, to create a licensing system for manufacturing processed cells, and in doing so to promote the prompt and safe provision of regenerative medicine.

Two points about scope matter for patients:

  • It covers medical care that uses processed cells (cells that have been cultured or otherwise processed), and, since the 2025 amendment, certain techniques that deliver nucleic acids into the body.
  • It does not cover clinical trials run for product approval, or approved regenerative medicine products used as approved (Article 2). Those fall under the pharmaceuticals law instead. So the two iPS cell–derived products that received conditional, time-limited approval on 6 March 2026 sit in a different system from a clinic's self-pay cell treatment. See Japan Approves the First iPS Cell–Derived Products.

In practice, the Act is the framework behind most cell treatments that private clinics in Japan offer on a self-pay basis.

The three risk classes

The Act sorts treatments into Class I (high risk), Class II (medium risk) and Class III (lower risk). The details are in Articles 2 and 3 of the Enforcement Regulations.

Class What falls into it Typical examples
Class I Treatments using ES cells, iPS cells or iPS-like cells; gene-modified cells; animal cells; cells from someone other than the patient; and in vivo delivery of nucleic acids into the patient's own cells iPS cell–derived treatments; allogeneic cells such as donated umbilical cord–derived cells
Class II Cultured stem cells; cultured cells used to rebuild, repair or form body structure or function; and any non-homologous use of cells (cells used for a different function than they serve in their original tissue) The patient's own cultured fat-derived stem cells; PRP injected into a joint
Class III Everything else covered by the Act Typically, the patient's own immune cell therapy

Allogeneic means Class I. Many international patients ask about "umbilical cord stem cells." Because these come from a donor rather than the patient, they fall under Class I, not Class II.

PRP depends on how it is used. Platelet-rich plasma is made from the patient's own blood and is not cultured, but the class turns on where it goes. The Japanese Orthopaedic Association's 2023 knee osteoarthritis guideline states that injecting PRP into a joint cavity, where blood flow is poor, is not homologous use, so it is a Class II technique. For other uses, the class is whatever the clinic's filed plan specifies. See PRP Therapy Explained.

The class of a specific treatment is set in the provision plan a clinic files, not in its marketing.

How this compares with the US. FDA uses a similar concept. Under 21 CFR 1271.10, cell and tissue products that are minimally manipulated and intended for homologous use only (among other criteria) are regulated solely under section 361 of the Public Health Service Act; products that do not meet those criteria and do not qualify for an exception in 21 CFR 1271.15 are regulated as drugs, devices or biologics. In Japan, failing the homologous-use test does not stop a clinic from offering a treatment. It places the treatment in Class II at least (Class I if, for example, donor cells are used), with a tougher committee review and a filed plan before any patient is treated.

Who reviews the plan: two kinds of committee

Every provision plan is reviewed by a committee certified by the Minister of Health, Labour and Welfare. There are two kinds:

  • Specially certified committees (tokutei nintei iinkai): may review Class I, II and III plans. Under Articles 7 and 11 of the Act, Class I and Class II plans must go to one of these.
  • Certified committees that review Class III only: may review Class III plans only.

The committee assesses the plan against the national provision standards and gives its opinion on whether the treatment may be offered and what the clinic must watch for. The clinic must attach that opinion when it files the plan.

Filing routes and the 90-day wait for Class I

After the committee review, the clinic files the plan. Under Article 4 of the Act, plans are submitted to the Minister of Health, Labour and Welfare; Article 118 of the Enforcement Regulations delegates the handling of Class II and Class III plans to the regional health and welfare bureaus. MHLW says plans, changes, discontinuations and reports are all filed through its online e-Saisei system.

Class Review committee Plan filed with Can treatment start on filing?
Class I Specially certified committee Minister of Health, Labour and Welfare No. The clinic must wait 90 days from filing
Class II Specially certified committee Regional health and welfare bureau (delegated) The Act sets no waiting period
Class III Certified committee (Class III only) or specially certified committee Regional health and welfare bureau (delegated) The Act sets no waiting period

The 90-day rule. Under Article 8, if the Minister finds that a Class I plan does not meet the provision standards, the Minister may order changes within 90 days of filing. The Minister can extend that period for reasonable cause, or shorten it if the plan is found to comply. Article 9 bars the clinic from providing the Class I treatment until the period has passed.

After filing: changes and periodic reports

Filing is not a one-time step. The Act imposes ongoing duties:

  • Changes to the plan (Article 5): before making a change, the clinic must get the committee's opinion again and file the revised plan. For minor changes defined by ministerial ordinance, it must notify the committee and the Minister within 10 days of making the change.
  • Discontinuation (Article 6): if the clinic stops offering the treatment, it must notify the committee and the Minister within 10 days.
  • Periodic reports (Enforcement Regulations Articles 37–38): every year, counted from the date the plan was filed, the clinic must report within 90 days of the period's end to both the committee and the Minister. Reports cover how many patients were treated, adverse events and their course, and an assessment of safety and scientific validity. The committee then gives its opinion on whether the treatment should continue.

Adverse event reporting: 7, 15 and 60 days

When a clinic learns of an illness, disability, death or infection suspected to be caused by the treatment, it must report within fixed deadlines (Enforcement Regulations Articles 35–36):

A gloved hand holds a clear lid above a multi-well plate with reddish liquid and a pipette, beside a culture flask and a centrifuge tube in a rack.

Event Deadline Report to
Death, or a case that could lead to death Within 7 days of learning of it Committee and Minister
Hospitalization or a longer hospital stay; disability or a case that could lead to disability; other serious cases; congenital disease or abnormality in later generations Within 15 days Committee and Minister
Other suspected treatment-related events Every 60 days from the filing date, within 10 days after each period ends Committee

For Class II and III treatments, the regional health and welfare bureau receives the reports addressed to the Minister.

Penalties under the 2026 text

Providing regenerative medicine without going through these procedures is a violation of the law, and MHLW states that penalties apply. Under the provisions of the Act as they stand in 2026:

  • Class I without a filed plan (or with a false plan, or before the 90-day period ends): up to one year of imprisonment (kokinkei) or a fine of up to 1 million yen (Article 60).
  • Class II or III without a filed plan: a fine of up to 500,000 yen (Article 62).
  • Breaching an emergency order: the Minister can order a clinic to suspend treatment to prevent harm to health from occurring or spreading (Article 22). Breaching such an order carries up to three years of imprisonment, a fine of up to 3 million yen, or both (Article 59).
  • Improvement orders and inspections: the Minister can order a plan to be changed, suspend treatment if that order is ignored, and send officials to inspect a clinic (Articles 23–24).

Where an employee commits these violations in the course of a clinic's business, the clinic's legal entity can also be fined (Article 64).

The 2025 amendment and the 2026 reporting window

The Act has been updated recently in two ways that matter for patients:

  • May 2025: MHLW reports that the Act, its Cabinet Order and its Enforcement Regulations were amended on 31 May 2025, and the amended Act took effect in May 2025. In vivo gene therapy, which does not use processed cells, became subject to the Act. MHLW notes that treatments using nucleic acids may also require procedures under Japan's Cartagena Act on genetically modified organisms.
  • 2 September 2026: MHLW opened a regenerative medicine information and reporting window. It accepts reports of suspected legal violations and safety concerns in regenerative medicine.

What this means if you are travelling for treatment

The system gives you a practical starting point. A compliant clinic will have a filed provision plan for the specific treatment it is offering you, naming the review committee and the risk class. Before you commit, ask the clinic:

  • Which class is this treatment under Japan's Safety Act?
  • Which certified committee reviewed the plan?
  • When was the plan filed, and is the treatment you are being offered the one described in it?

Plans are filed treatment by treatment, so a clinic that has filed for one therapy has not necessarily filed for another. If a clinic cannot answer, or tells you its treatment needs no filing, treat that as a warning sign.

Send the clinic's name and its treatment plan to our advisors, and we'll check whether it has filed a provision plan for that treatment and whether the class matches what you are being told. Stem Cell Japan provides consultation and coordination for regenerative medicine in Japan; treatment is provided by Japanese medical institutions. For the wider picture, see How Japan regulates regenerative medicine, Getting treated in Japan and How to Tell Whether a Japanese Regenerative Medicine Clinic Is Compliant. You can also start with our Pre-screening.

A filed plan shows that the clinic has completed the legal procedure. It is not evidence that the treatment works for your condition or that it carries no risk.

Frequently asked questions

Which class is stem cell therapy in Japan?

It depends on the cells. Treatments using iPS or ES cells, or cells from a donor (including umbilical cord–derived cells), are Class I. Treatments using the patient's own cultured stem cells, such as fat-derived stem cells, are Class II. The class of a specific treatment is the one stated in the clinic's filed plan.

Is PRP Class II or Class III?

It depends on how it is used. PRP injected into a joint is a Class II technique because it is not homologous use. For other uses, the class is whatever the clinic's filed plan specifies.

Why does Class I have a 90-day wait?

Class I carries the highest risk. For 90 days after filing, the Minister of Health, Labour and Welfare can order changes if the plan does not meet the provision standards, and the clinic may not provide the treatment until that period ends. The period can be extended or shortened.

How quickly must a clinic report a serious side effect?

Within 7 days for a death or a case that could lead to death, and within 15 days for hospitalization, disability or other serious cases. Both go to the review committee and to the Ministry, with the regional bureau receiving reports for Class II and III.

Does an approved iPS cell product fall under the Safety Act?

No, not when it is used as approved. Approved regenerative medicine products used within their approved conditions are regulated under Japan's pharmaceuticals law, while clinic treatments using processed cells fall under the Safety Act.

Sources: Act on the Safety of Regenerative Medicine (Act No. 85 of 2013) and its Enforcement Regulations (MHLW Ordinance No. 110 of 2014), current text via the e-Gov law database; MHLW page on regenerative medicine, cell therapy and gene therapy; Japanese Orthopaedic Association Clinical Practice Guideline for Knee Osteoarthritis 2023, reference material 2; US Code of Federal Regulations, 21 CFR 1271.10 and 1271.20; JST Science Portal (18 March 2026). Checked November 2026; MHLW publications prevail.

Medical disclaimer: This site provides general information only and does not constitute medical advice; whether any treatment is suitable for you must be decided by a doctor after an in-person consultation.